InvestorsHub Logo
Followers 14
Posts 2910
Boards Moderated 1
Alias Born 03/16/2005

Re: Sunman88 post# 856

Saturday, 05/18/2024 8:59:46 AM

Saturday, May 18, 2024 8:59:46 AM

Post# of 1437
Sunman, I don't believe the 75% reference was properly defined in your discussion. Here's the section discussing the 75% number (from the Q1 call transcript):

"Early launch data indicates that more than 75% of patients enrolled for Amtagvi are commercially insured which aligns with our expectations."

From the following, per Jim Ziegler: "...We are observing month over month growth and we anticipate sustained growth throughout the year as the number of ATCs expand and there is broader utilization of Amtagvi. In the short time since approval, favorable reimbursement trends and medical coverage policies have set us up for success and broad access for patients. Early launch data indicates that more than 75% of patients enrolled for Amtagvi are commercially insured which aligns with our expectations. Thus far payers responsible for more than 200 million lives have approved at least one patient for Amtagvi treatment and notably 13 payers responsible for approximately 90 million covered lives have already published medical coverage policies that are consistent with label, clinical trials and the recently updated NCCN guidelines..."

https://uk.finance.yahoo.com/news/iovance-biotherapeutics-inc-nasdaq-iova-163350605.html

Please share your thoughts after reviewing this section again if you would, please.

I think any discussion of actual reimbursement amounts is speculative, but the analysts hopefully have a handle on some of that in what they offered regarding revenues for the coming Q's.

If anyone has actual experience with CAR-T reimbursement, that might help a bit.

Regarding the aggressive shorting, that may simply be the perfect storm of timing. Sell the news following Q1 call, insiders can't trade currently due to SEC rules (assuming non-public material info), and some major funds that have ties to insiders even though they don't own 10% may also be holding back from trading to avoid appearance of impropriety and insider trading violations.

Shorts may have free reign right now and if they know they do, wouldn't they take advantage?

Just a few thoughts.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IOVA News